Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models

Cancer immunotherapy holds great promise, yet its efficacy and applicability can be hampered by the rise of systemic toxicities. We have recently shown that the lethal side effects of cancer immunotherapy are markedly exacerbated with aging. Blocking tumor necrosis factor α or macrophages can allevi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouchlaka, Myriam N, Murphy, William J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909540/
https://www.ncbi.nlm.nih.gov/pubmed/24498569
http://dx.doi.org/10.4161/onci.27186
_version_ 1782301865396928512
author Bouchlaka, Myriam N
Murphy, William J
author_facet Bouchlaka, Myriam N
Murphy, William J
author_sort Bouchlaka, Myriam N
collection PubMed
description Cancer immunotherapy holds great promise, yet its efficacy and applicability can be hampered by the rise of systemic toxicities. We have recently shown that the lethal side effects of cancer immunotherapy are markedly exacerbated with aging. Blocking tumor necrosis factor α or macrophages can alleviate the systemic toxicity of immunotherapy while preserving its antineoplastic effects.
format Online
Article
Text
id pubmed-3909540
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39095402014-02-04 Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models Bouchlaka, Myriam N Murphy, William J Oncoimmunology Author's View Cancer immunotherapy holds great promise, yet its efficacy and applicability can be hampered by the rise of systemic toxicities. We have recently shown that the lethal side effects of cancer immunotherapy are markedly exacerbated with aging. Blocking tumor necrosis factor α or macrophages can alleviate the systemic toxicity of immunotherapy while preserving its antineoplastic effects. Landes Bioscience 2013-12-01 2013-12-09 /pmc/articles/PMC3909540/ /pubmed/24498569 http://dx.doi.org/10.4161/onci.27186 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Bouchlaka, Myriam N
Murphy, William J
Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models
title Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models
title_full Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models
title_fullStr Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models
title_full_unstemmed Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models
title_short Impact of aging in cancer immunotherapy: The importance of using accurate preclinical models
title_sort impact of aging in cancer immunotherapy: the importance of using accurate preclinical models
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909540/
https://www.ncbi.nlm.nih.gov/pubmed/24498569
http://dx.doi.org/10.4161/onci.27186
work_keys_str_mv AT bouchlakamyriamn impactofagingincancerimmunotherapytheimportanceofusingaccuratepreclinicalmodels
AT murphywilliamj impactofagingincancerimmunotherapytheimportanceofusingaccuratepreclinicalmodels

Ejemplares similares